Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The portfolio has 1 pending office action in Biotechnology & Pharmaceuticals. The matter involves 1 distinct examiner and 1 distinct art unit, placing the pending prosecution activity within a single examination setting.
MIKNIS, ZACHARY J is the busiest examiner, with 1 pending matter. Practitioners can direct their review toward that examiner and the identified art unit when assessing amendments and argument strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 1 | 68.5% | +32.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686711 | GLP-1R AGONISTS FOR USE IN A TREATMENT OF NEUROLOGIAL IMPAIRMENT ASSOCIATED WITH VIRAL INFECTION | MIKNIS, ZACHARY J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686711 | GLP-1R AGONISTS FOR USE IN A TREATMENT OF NEUROLOGIAL IMPAIRMENT ASSOCIATED WITH VIRAL INFECTION | MIKNIS, ZACHARY J | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Feb 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNeuraly Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Zachary J Miknis has the most, with 1 of Neuraly Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
